A metabolome-wide association study in the general population reveals decreased levels of serum laurylcarnitine in people with depression
Authors:
Open Access
- 4 June 2021
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 26 (12) , 7372-7383
Abstract
Depression constitutes a leading cause of disability worldwide. Despite extensive research on its interaction with psychobiological factors, associated pathways are far from being elucidated. Metabolomics, assessing the final products of complex biochemical reactions, has emerged as a valuable tool for exploring molecular pathways. We conducted a metabolome-wide association analysis to investigate the link between the serum metabolome and depressed mood (DM) in 1411 participants of the KORA (Cooperative Health Research in the Augsburg Region) F4 study (discovery cohort). Serum metabolomics data comprised 353 unique metabolites measured by Metabolon. We identified 72 (5.1%) KORA participants with DM. Linear regression tests were conducted modeling each metabolite value by DM status, adjusted for age, sex, body-mass index, antihypertensive, cardiovascular, antidiabetic, and thyroid gland hormone drugs, corticoids and antidepressants. Sensitivity analyses were performed in subcohorts stratified for sex, suicidal ideation, and use of antidepressants. We replicated our results in an independent sample of 968 participants of the SHIP-Trend (Study of Health in Pomerania) study including 52 (5.4%) individuals with DM (replication cohort). We found significantly lower laurylcarnitine levels in KORA F4 participants with DM after multiple testing correction according to Benjamini/Hochberg. This finding was replicated in the independent SHIP-Trend study. Laurylcarnitine remained significantly associated (pvalue < 0.05) with depression in samples stratified for sex, suicidal ideation, and antidepressant medication. Decreased blood laurylcarnitine levels in depressed individuals may point to impaired fatty acid oxidation and/or mitochondrial function in depressive disorders, possibly representing a novel therapeutic target.Keywords
This publication has 78 references indexed in Scilit:
- Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010PLOS Medicine, 2013
- Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole PathwayPLOS ONE, 2013
- Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic ProfileScientific Reports, 2012
- The Psychiatric Manifestations of Mitochondrial DisordersThe Journal of Clinical Psychiatry, 2012
- Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of conceptTranslational Psychiatry, 2011
- Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological SettingPLOS ONE, 2010
- Salivary cortisol in depressed patients versus control persons: A systematic review and meta-analysisPsychoneuroendocrinology, 2010
- Cohort Profile: The Study of Health in PomeraniaInternational Journal of Epidemiology, 2010
- Metabolomic Differences in Heart Failure Patients With and Without Major DepressionJournal of Geriatric Psychiatry and Neurology, 2010
- Metabolomics tools for identifying biomarkers for neuropsychiatric diseasesNeurobiology of Disease, 2009